高级检索
当前位置: 首页 > 详情页

microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2

文献详情

资源类型:
机构: [1]Guangzhou Med Univ, Dept Radiat Oncol, Ctr Canc, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [2]Sun Yat Sen Univ, Ctr Canc, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510060, Guangdong, Peoples R China; [3]Sun Yat Sen Univ, Ctr Canc, Dept Gynecol, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: nasopharyngeal carcinoma microRNAs metastases microRNA-125b

摘要:
Multidrug resistance (MDR) is a major clinical obstacle in the successful treatment of patients with metastatic nasopharyngeal carcinoma (NPC). Results from previous studies suggest that microRNAs (miRNA) may be involved in promoting MDR in multiple cancer types. However, the role of miR-125b in modulating the MDR of NPC is elusive. In the present study, miR-125b expression in cisplatin (DDP)-resistant CNE2 cells (CNE2/DDP) was compared with parental counterparts, using reverse transcription-quantitative polymerase chain reaction. A >3-fold reduction in miR-125b expression levels was observed in CNE2/DDP cells compared with parental CNE2 cells. Ectopic expression of miR-125b by transfecting CNE2/DDP cells with miR-125b mimics, increased DDP-induced cytotoxicity, apoptosis and chemosensitivity. By contrast, suppression of miR-125b by transfecting CNE2 cells with miR-125b inhibitors, reduced DDP-induced cytotoxicity and apoptosis, and facilitated cisplatin resistance. The results suggest that miR-125b may regulate the sensitivity of NPC cells to DDP by modulating the expression levels of antiapoptotic factor B-cell CLL/lymphoma 2. Collectively, the results of the present study highlight miR-125b as a potential therapeutic target for reversing MDR in NPC.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
第一作者:
第一作者机构: [1]Guangzhou Med Univ, Dept Radiat Oncol, Ctr Canc, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [2]Sun Yat Sen Univ, Ctr Canc, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510060, Guangdong, Peoples R China;
通讯作者:
通讯机构: [1]Guangzhou Med Univ, Dept Radiat Oncol, Ctr Canc, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [2]Sun Yat Sen Univ, Ctr Canc, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510060, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43373 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号